Key result
Rhythm control therapy in persistent atrial fibrillation significantly improved flow-mediated dilation from 6.3% at baseline to 7.6% at 9 months, indicating enhanced endothelial function despite heterogeneous systemic inflammatory responses.
Why the study?
While inflammation contributes to AF pathogenesis, whether AF itself contributes to systemic inflammation remains elusive, prompting evaluation of the impact of rhythm control on systemic inflammation and endothelial function.
Does rhythm control therapy improve endothelial function and systemic inflammation in patients with persistent atrial fibrillation?
Cohort (n=124)
No
Does rhythm control therapy improve endothelial function and systemic inflammation in patients with persistent atrial fibrillation?
Answers are grounded in this paper and cite their sources.
Successful rhythm control in persistent atrial fibrillation improves endothelial function, an effect likely mediated by hemodynamic restoration rather than a uniform anti-inflammatory effect.
Background: Atrial fibrillation (AF) is associated with systemic inflammation, endothelial dysfunction, and adverse cardiovascular outcomes. While there is robust evidence, that inflammation contributes to AF pathogenesis, the existence of a reverse relation - whether AF contributes to inflammation - remains elusive. This study therefore evaluates the impact of rhythm control on systemic inflammation and endothelial function. Methods: In this prospective observational study, 124 patients with persistent AF undergoing successful rhythm control therapy (electrical cardioversion or catheter ablation) were followed for nine months. Various Cytokines, high-sensitivity C-reactive protein (hsCRP), flow-mediated dilation (FMD) and additional inflammatory biomarkers were measured at baseline, 1 week, 1 month, 3 months, and 9 months. FMD was assessed by high-resolution brachial artery ultrasound. Patients with AF recurrence throughout the follow-up period were excluded from primary analysis. Results: In patients without AF recurrence, FMD improved significantly from 6.3 % (4.6-8.3) to 7.6 % (5.1-8.8) (p < 0.001). HsCRP, IL-8 and fibrinogen declined modestly (p = 0.002, p < 0.001 and p < 0.001, respectively), whereas IL-2, IP-10, IL-12p70, MCP-1 and TNF-α increased significantly over time (all p < 0.001). Elevated pre-treatment hsCRP was weakly associated with AF recurrence (r = 0.20, p = 0.023; AUC = 0.61). IL-6 showed temporal variation but no sustained change from baseline. Conclusion: Rhythm control therapy in persistent AF is associated with an improvement of endothelial function but not with a homogeneous improvement of systemic inflammatory serological profiles. Thus, the improvement in FMD appears to be mediated primarily by hemodynamic restoration rather than anti-inflammatory effects.
No takes yet. Share an insight, caveat, or question.
Seidel et al. (2026) conducted a cohort in Persistent atrial fibrillation (n=124). Rhythm control therapy (electrical cardioversion or catheter ablation) vs. Baseline (Pre-treatment) was evaluated on Flow-mediated dilation (FMD) at 9 months in patients without AF recurrence (p=<0.001). Rhythm control therapy in persistent atrial fibrillation significantly improved flow-mediated dilation from 6.3% at baseline to 7.6% at 9 months, indicating enhanced endothelial function despite heterogeneous systemic inflammatory responses.
Synapse has enriched 10 related papers. Consider them for comparative context: